- Home
- ACON vs SLRX Comparison
ACON vs SLRX Comparison
Compare ACON & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACON
- SLRX
- Stock Information
- Founded
- ACON 2008
- SLRX N/A
- Country
- ACON United States
- SLRX United States
- Employees
- ACON N/A
- SLRX N/A
- Industry
- ACON Retail: Computer Software & Peripheral Equipment
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ACON Technology
- SLRX Health Care
- Exchange
- ACON Nasdaq
- SLRX Nasdaq
- Market Cap
- ACON 1.7M
- SLRX 2.0M
- IPO Year
- ACON 2022
- SLRX N/A
- Fundamental
- Price
- ACON $0.11
- SLRX $1.22
- Analyst Decision
- ACON Buy
- SLRX
- Analyst Count
- ACON 2
- SLRX 0
- Target Price
- ACON $1.30
- SLRX N/A
- AVG Volume (30 Days)
- ACON 991.9K
- SLRX 30.5K
- Earning Date
- ACON 11-14-2024
- SLRX 11-14-2024
- Dividend Yield
- ACON N/A
- SLRX N/A
- EPS Growth
- ACON N/A
- SLRX N/A
- EPS
- ACON N/A
- SLRX N/A
- Revenue
- ACON $49,289.00
- SLRX N/A
- Revenue This Year
- ACON N/A
- SLRX N/A
- Revenue Next Year
- ACON $186.36
- SLRX N/A
- P/E Ratio
- ACON N/A
- SLRX N/A
- Revenue Growth
- ACON N/A
- SLRX N/A
- 52 Week Low
- ACON $0.10
- SLRX $1.22
- 52 Week High
- ACON $7.39
- SLRX $7.20
- Technical
- Relative Strength Index (RSI)
- ACON 30.75
- SLRX 35.59
- Support Level
- ACON $0.16
- SLRX $1.35
- Resistance Level
- ACON $0.20
- SLRX $1.67
- Average True Range (ATR)
- ACON 0.02
- SLRX 0.12
- MACD
- ACON -0.01
- SLRX -0.02
- Stochastic Oscillator
- ACON 13.37
- SLRX -15.38
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.